Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 60.5%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 179,400 shares, a growth of 60.5% from the October 15th total of 111,800 shares. Based on an average daily volume of 554,000 shares, the short-interest ratio is currently 0.3 days. Currently, 19.1% of the shares of the stock are short sold.

Allarity Therapeutics Price Performance

ALLR stock opened at $1.45 on Thursday. The firm has a fifty day moving average price of $2.13 and a 200 day moving average price of $8.53. Allarity Therapeutics has a fifty-two week low of $1.26 and a fifty-two week high of $666.00.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.